David B. Rein

38.8k citations

83 papers · 4.1k indexed · 4 hit papers · h-index 27

Hepatology top 0.2%
Epidemiology top 1%
Ophthalmology top 0.5%
Radiology, Nuclear Medicine and Imaging top 2%
Infectious Diseases top 2%

Co-authors: John S. Wittenborn Bryce D. Smith Gretchen A Stevens Steven Wiersma John W. Ward Nita Patel Cindy M. Weinbaum Sarah B. Lesesne
Topics: Hepatitis C virus research (21 papers)Retinal Diseases and Treatments (19 papers)Retinal Imaging and Analysis (18 papers)
Cited by: Hepatology Ophthalmology Epidemiology
Journals: The Lancet Annals of Internal Medicine Hepatology
Partner nations: United States Kenya Saudi Arabia

In The Last Decade

David B. Rein

78 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

2012 785 citations Bryce D. Smith, David B. Rein et al. PubMed profile →
The global burden of hepatitis E virus genotypes 1 and 2 in 2005

2011 533 citations David B. Rein, Gretchen A Stevens et al. Hepatology profile →
The Economic Burden of Major Adult Visual Disorders in the United States

2006 489 citations David B. Rein profile →
Prevalence of Age-Related Macular Degeneration in the US in 2019

2022 132 citations David B. Rein, John S. Wittenborn et al. JAMA Ophthalmology profile →

Peers

Countries citing papers authored by David B. Rein

Since Specialization

Citations

This map shows the geographic impact of David B. Rein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Rein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Rein more than expected).

Fields of papers citing papers by David B. Rein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Rein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Rein. The network helps show where David B. Rein may publish in the future.

Co-authorship network of co-authors of David B. Rein

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Rein. A scholar is included among the top collaborators of David B. Rein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Rein. David B. Rein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Telemedicine-Based Risk Program to Prevent Falls Among Older Adults: Protocol for a Randomized Quality Improvement Trial 2024 ·JMIR Research Protocols ·David B. Rein,Madeleine E. Hackney,Yara K. Haddad,(unknown),Briana Moreland,(unknown),Cora Peterson,(unknown),(unknown),Camille P. Vaughan,Theodore M. Johnson,Gwen Bergen,(unknown)	0
2	Validity of Administrative Claims and Electronic Health Registry Data From a Single Practice for Eye Health Surveillance 2023 ·JAMA Ophthalmology ·John S. Wittenborn,Aaron Lee,Elizabeth A. Lundeen,Phoebe A. Lamuda,Jinan Saaddine,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Ryan T. Yanagihara,(unknown),(unknown),Marian Blazes,David B. Rein	3
3	A Mixed-Methods Approach for Evaluating Implementation Processes and Program Costs for a Hypertension Management Program Implemented in a Federally Qualified Health Center 2023 ·Prevention Science ·(unknown),(unknown),John S. Wittenborn,David B. Rein,Ashley Marshall,(unknown),(unknown),Natalie G. Nelson,(unknown),Roy Ahn	1
4	Comparing Telephone Survey Responses to Best-Corrected Visual Acuity to Estimate the Accuracy of Identifying Vision Loss: Validation Study 2023 ·JMIR Public Health and Surveillance ·John S. Wittenborn,Aaron Lee,Elizabeth A. Lundeen,Phoebe A. Lamuda,Jinan Saaddine,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Ryan T. Yanagihara,(unknown),(unknown),Marian Blazes,David B. Rein	3
5	Vision Impairment and Blindness Prevalence in the United States 2020 ·Ophthalmology ·David B. Rein,Phoebe A. Lamuda,John S. Wittenborn,(unknown),(unknown),Bonnielin K. Swenor,Jinan Saaddine,Elizabeth A. Lundeen	24
6	Detecting age-related macular degeneration (AMD) biomarker images using MFCC and texture features 2020 ·Yiyang Wang,(unknown),(unknown),(unknown),David B. Rein,Amani A. Fawzi,Jacob Furst,Daniela Raicu	6
7	Hepatitis C virus testing for case identification in persons born during 1945‐1965: Results from three randomized controlled trials 2017 ·Hepatology ·Anthony Yartel,David B. Rein,Kimberly Brown,Katherine Krauskopf,Omar Massoud,Cynthia L. Jordan,(unknown),Alex D. Federman,David R. Nerenz,Joanne E. Brady,(unknown),Bryce D. Smith	16
8	Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST‐C study 2016 ·Hepatology ·Joanne E. Brady,(unknown),Anthony Yartel,(unknown),Alex D. Federman,Joseph Kannry,Cynthia L. Jordan,Omar Massoud,David R. Nerenz,Kimberly Brown,Bryce D. Smith,Claudia Vellozzi,David B. Rein	20
9	Parallel 23: Fatty Liver Disease: Clinical and Therapeutic I 2015 ·Hepatology ·Richard Pencek,Tracy J. Mayne,Marco Carbone,George Mells,Jennifer R. Kramer,Peter Richardson,(unknown),Hashem B. El‐Serag,David B. Rein	2
10	The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus 2015 ·Clinical Infectious Diseases ·David B. Rein,John S. Wittenborn,Bryce D. Smith,(unknown),John W. Ward	105
11	Attributes Associated with Eye Care Use in the United States: A Meta-Analysis 2013 ·Ophthalmology ·Laura Danielle Wagner,David B. Rein	43
12	Vision Problems Are a Leading Source of Modifiable Health Expenditures 2013 ·Investigative Ophthalmology & Visual Science ·David B. Rein	21
13	The global burden of hepatitis E virus genotypes 1 and 2 in 2005breakdown → 2011 ·Hepatology ·David B. Rein,Gretchen A Stevens,(unknown),John S. Wittenborn,Steven Wiersma	533
14	Cost-Effectiveness of Glaucoma Interventions in Barbados and Ghana 2010 ·Optometry and Vision Science ·John S. Wittenborn,David B. Rein	32
15	Prevalence of Hepatitis B Surface Antigen Among Refugees Entering the United States Between 2006 and 2008 2009 ·Hepatology ·David B. Rein,Sarah B. Lesesne,Ann O’Fallon,Cindy M. Weinbaum	23
16	Estimating Quality-Adjusted Life Year Losses Associated with Visual Field Deficits Using Methodological Approaches 2007 ·Ophthalmic Epidemiology ·David B. Rein,Kathleen E. Wirth,Chris A. Johnson,Paul P. Lee	22
17	The Impact of 317 Immunization Program Funding 2006 ·American Journal of Public Health ·David B. Rein,Amanda Honeycutt,Lucia Rojas Smith,James Hersey	4
18	Peer Reviewed: A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program 2006 ·Preventing Chronic Disease ·David B. Rein,Diane Orenstein,(unknown),Hong Chen,Patricia A. Jones,J. Nell Brownstein,Rosanne P. Farris	2
19	Mental health disorders and sexually transmitted diseases in a privately insured population. 2004 ·PubMed ·David B. Rein,Lynda A. Anderson,Kathleen L. Irwin	11
20	Medical Care Expenditures for Genital Herpes in the United States 2000 ·Sexually Transmitted Diseases ·Guoyu Tao,William J. Kassler,David B. Rein	32

About David B. Rein

David B. Rein is a scholar working on Hepatology, Ophthalmology and Epidemiology, having authored 83 papers that have together received 4.1k indexed citations. Recurring topics across this work include Hepatitis C virus research (21 papers), Retinal Diseases and Treatments (19 papers) and Retinal Imaging and Analysis (18 papers). The work is most often cited by research in Hepatology (2.1k citations), Ophthalmology (1.1k citations) and Epidemiology (2.0k citations). David B. Rein has collaborated with scholars based in United States, Kenya and Saudi Arabia. Frequent co-authors include John S. Wittenborn, Bryce D. Smith, Gretchen A Stevens, Steven Wiersma, John W. Ward, Nita Patel, Cindy M. Weinbaum, Sarah B. Lesesne, Anthony Yartel and Amy Jewett. Their work appears in journals such as The Lancet, Annals of Internal Medicine and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact